In the first year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a World Health Organization (“WHO”) brief released in March 2022 (https://ibn.fm/NIX0U). The brief also highlights who has been most affected and summarizes the pandemic’s effect on the availability of mental health services. Data compiled by the WHO, including statistics from the latest Global Burden of Disease study, identifies young people and women as the most vulnerable populations for mental health disorders at the hand of the pandemic – with young people carrying a disproportionate risk for suicide or self-harming behavior.
The WHO pointed out in their brief that there is a shortage of mental health resources globally which extends to the present. The most recent WHO Mental Health Atlas shows that in 2020, governments worldwide spent an average of 2% of their health budgets on mental health, with low-income countries reporting less than one mental health worker per 100,000 people.
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) was founded in 2020 as a response to the lack of innovation addressing mental health treatment. Mydecine is currently developing innovative first- and second-generation novel therapeutics to treat the unmet need in mental health and addiction disorders. The company focuses on psychedelic compounds and other novel molecules with therapeutic potential.
There is increased focus on the therapeutic potential of psychedelic drugs, as the market is expected to gain momentum and expand from an estimated value of $2.82 billion in 2022 to approximately $7.57 billion by 2028. Driving factors of growth in this market include the rising prevalence of mental depression and anxiety, in addition to the availability of off-label drugs, which have propelled the demand for psychedelic drug options within the market (https://ibn.fm/c0rfm).
Mydecine also targets mental health disorders like Post Traumatic Stress Disorder (“PTSD”). In 2020, the global market for PTSD therapeutics was valued at $2.3 billion. By 2027, this market is expected to grow to $3.1 billion, growing at a CAGR of 4.3% over the forecast period (https://ibn.fm/H6UF2). The company’s current pipeline consists of drug candidates that provide a variety of enhancements and are part of psychedelic-assisted therapy programs which are in clinical trial or pre-trial stages as potential treatments for PTSD and smoking cessation.
Mydecine’s wholly-owned subsidiary Mindleap features a platform that is the first international virtual health platform that includes psychedelic integration. Mindleap provides features for introduction and post-care integration, including:
Mindleap is leveraging a global healthcare IT market valued at $74.2 billion in 2020. This market is expected to grow at a CAGR of 10.7% over the forecasted period (https://ibn.fm/UqtsZ). The increased adoption of preventative care, more funding for health startups, growing network coverage, improved infrastructure, and advancements in technology, are all contributing market growth factors. The Mindleap healthcare platform is available for iOS and Android download today in the app store (www.Mindleap.com).
For more information, visit the company’s website at www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
According to a recent study, individuals who have used classic psychedelics like LSD or psilocybin…
There is a growing trend in which parents take tiny doses of psychedelics like LSD…
Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to…
A new study has found that while all ethnic and racial groups can benefit from…
A new study that is yet to be peer-reviewed has found that rats given psilocybin…
The American embassy in Peru has warned Americans against taking traditional psychedelics like the ayahuasca…